Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
(updated content) |
m (categories) |
||
| Line 18: | Line 18: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Androgen receptor inhibitors]] | ||
| + | [[Category:Prostate cancer medications]] | ||
Revision as of 01:39, 8 October 2012
Also known as Cosudex, Calutide, or Kalumid.
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert pages 20-24[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]